RQ-PCR在慢性粒细胞白血病细胞BCR-ABL融合基因检测中的应用

发布时间：2018-06-28 01:56

本文选题：慢性粒细胞白血病 + BCR-ABL　；参考：《检验医学与临床》2016年22期

【摘要】：目的探讨采用实时荧光定量逆转录聚合酶链反应(RQ-PCR)技术检测慢性粒细胞白血病(CML)细胞的BCRABLp210融合基因的临床价值。方法应用RQ-PCR技术对60例CML患者骨髓细胞BCR-ABLp210融合基因进行定量检测分析。结果 60例BCR-ABLp210融合基因阳性的CML患者中,慢性期33例,加速期13例,急变期14例,且CML急变期患者BCR-ABLp210转录本水平明显高于慢性期和加速期患者。经异基因造血干细胞移植治疗或经伊马替尼治疗6个月后,BCRABLp210转录本水平均较6个月前明显降低。但这两种方法治疗CML患者12个月后的效果比较差异无统计学意义(P0.05),而采用其他酪氨酸激酶抑制剂治疗CML 12个月后也可达到相似的治疗效果。结论 RQ-PCR技术监测CML患者细胞BCR-ABLp210融合基因表达有助于CML的诊断、治疗效果评价及微小残留的监测。
[Abstract]:Objective to investigate the clinical value of real-time fluorescent quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) in detecting BCR ABL p210 fusion gene in chronic myeloid leukemia (CML) cells. Methods BCR-ABLp210 fusion gene in bone marrow cells of 60 CML patients was quantitatively detected by RQ-PCR. Results among 60 CML patients with positive BCR-ABLp210 fusion gene, 33 cases were in chronic stage, 13 cases in accelerated phase and 14 cases in blast phase. The level of BCR-ABLp210 transcript in CML patients was significantly higher than that in chronic phase and accelerated phase. After 6 months of allogeneic hematopoietic stem cell transplantation or imatinib treatment, the level of BCRABLp210 transcripts was significantly lower than that of 6 months ago. However, there was no significant difference between the two methods after 12 months (P0.05), while other tyrosine kinase inhibitors could achieve similar results after 12 months of CML treatment. Conclusion Detection of BCR-ABLp210 fusion gene expression in CML cells by RQ-PCR is helpful to the diagnosis of CML, evaluation of therapeutic effect and monitoring of minimal residual.
【作者单位】：武汉大学人民医院检验科;武汉大学人民医院血液内科;
【基金】：国家自然科学基金资助项目(81200389,81501427) 教育部高等学校博士学科点专项科研基金(20120141120077) 湖北省自然科学基金资助项目(2016CFB456)
【分类号】：R733.72;R730.43

【相似文献】